Welcome to Sherry's CaringBridge site! We've created it to update friends, family, our Grace Community Chapel (http://www.gcchapel.org/
) family, and fellow multiple myeloma survivors. We appreciate your support and words of hope and encouragement during this time when it matters most.
Sherry was diagnosed with multiple myeloma just before Thanksgiving Day in 2013 at Progress West Hospital in St. Peters, MO and she was immediately transferred to Barnes Jewish Hospital (http://www.barnesjewish.org/
) and Siteman Cancer Center (https://siteman.wustl.edu/
) in Saint Louis. Sherry received world-class care from all of the doctors, nurses, and support staff during her initial hospitalization at Siteman. Her treatment plan included dozens of sensitive blood tests, x-rays, a PET scan, a lumbar puncture (spinal tap), pain medication, and chemotherapy treatment (cy-bor-dex or cytoxan, Velcade [bortezomib], and dexamethasone). Sherry's "unstoppable" determination to overcome the initial shock of her diagnosis, extreme pain, and withering fatigue paid off, and she was discharged before Christmas Day. In 2014 Sherry underwent vertebroplasty, a difficult hospitalization to receive an autologous stem cell transplant (http://www.mayoclinic.org/tests-procedures/stem-cell-transplant/basics/definition/prc-20013565
), and she began a maintenance treatment plan with a multiple myeloma drug called Revlimid.
Unfortunately, the multiple myeloma cancer became refractory to the Revlimid treatment plan in May 2015, and her hematologist-oncologist, Dr. Keith Stockerl-Goldstein (https://wuphysicians.wustl.edu/for-patients/find-a-physician/keith-e-stockerl-goldstein
) prescribed a new plan with a recently approved drug called Kyprolis. Since Sherry is a high-risk multiple myeloma patient, her treatment plans are effective for a limited time. Unfortunately the Kyprolis (carfilzomib) treatment plan was effective for only a few months. Sherry was then prescribed two additional treatment plans. Darzalex (or Daratumumab), which was still in a phase III clinical trial, was prescribed in fall 2015, and in early 2016 Sherry was switched to Empliciti (elotuzumab); however, both treatments failed to keep her IgA numbers and the disease in check. Sherry was prescribed cy-bor-dex chemotherapy and her multiple myeloma was controlled effectively for four months. During July and August 2016, Sherry was a patient in a BCMA CAR-T cell therapy clinical trial at Abramson Cancer Center / Penn Medicine Hospital in Philadelphia, PA. The phase 0 clinical trial failed to achieve a favorable outcome and Sherry is no longer in the CAR-T cell therapy clinical trial. During September 2016 Sherry was diagnosed with two plasmacytomas - one in her sphenoid sinus and another on a rib bone. Sherry was hospitalized at Siteman Cancer Center and underwent radiation treatment and resumed cy-bor-dex chemotherapy. In December 2016, the MM became refectory to Velcade (cy-bor-dex) and she was hospitalized for inpatient DCEP chemotherapy treatment. After recovering from a prescribed second round of DCEP chemo in late January, or early February, and when her multiple myeloma is stabilized the next treatment option will likely be an allogeneic stem cell transplant.
Thank you for visiting Sherry's CaringBridge website today. Your prayers, thoughts, questions, and words of encouragement will help make this site successful. May God bless you.
- I can do all things through Christ who strengthens me. Philippians 4:13
Bradley and Sherry Whitford